Uganda - English - National Drug Authority

f. hoffmann la-roche - rituximab - parenteral ordinary infusion vials/bottles - 100mg/10ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

reckitt benckiser pharmaceuticals proprietary limited, south africa - sodium alginate , sodium bicarbonate - suspension, oral - 500mg/10 ml + 267 mg/10 ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - dipotassium hydrogen phosphate 1,74 g/10 ml; potassium dihydrogen phosphate 1,36 g/10 ml - concentrate for solution for infusion - 1,36 g/10 ml - 1,74 g/10 ml - potassium dihydrogen phosphate 136 mg/ml; potassium hydrogen phosphate 174 mg/ml - potassium phosphate, incl. combinations with other potassium salts

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

10 ml glass vial -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

10 ml vial x 2 -

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - ketamine hydrochloride, quantity: 57.67 mg/ml (equivalent: ketamine, qty 50 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - ketamine interpharma? is recommended:,1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine interpharma ? is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - ketamine hydrochloride, quantity: 11.53 mg/ml (equivalent: ketamine, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - ketamine interpharma? is recommended:,1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine interpharma ? is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).